Breaking News

FORMA Names Medicinal, CompChemistry VP

By Kristin Brooks | January 7, 2014

Dinsmore brings extensive discovery and development expertise

Christopher Dinsmore, Ph.D., has been appointed vice president of Medicinal and Computational Chemistry at FORMA Therapeutics. Dr. Dinsmore joins the company after 19 years with Merck & Co., where he helped build the Merck Research Lab in Boston.
 
Dr. Dinsmore most recently served as executive director of Discovery Chemistry at Merck, where he led the discovery and advancement of seven compounds in clinical development, as well as several additional preclinical candidates. He has held various scientific and managerial leadership positions including membership in strategic committees managing external research partnerships and oncology in-licensing opportunities. 
 
“Chris is an experienced chemist and team leader with a broad background in the identification and development of therapeutics for oncology and cardiovascular diseases, Alzheimer's, asthma and rheumatoid arthritis,” said Kenneth W. Bair, Ph.D., chief scientific officer and head of R&D at FORMA Therapeutics. “As a founding member of Merck’s Boston site, he helped build highly integrated and collaborative new approaches to discovery research, which is precisely what FORMA strives to accomplish.”
 
  • API Sourcing Trends

    Kristin Brooks, Contract Pharma||April 11, 2016
    Drug product complexities, quality and regulatory hurdles drive market shift

  • Setting a Precedent for Biosimilars in the U.S.

    Setting a Precedent for Biosimilars in the U.S.

    Kristin Brooks, Contract Pharma||May 19, 2015
    Niall Dinwoodie of Charles River discusses several key industry issues on biosimilars and addresses some of the development and regulatory hurdles that remain

  • API Sourcing Trends

    API Sourcing Trends

    Kristin Brooks, Contract Pharma||March 19, 2015
    Ed Price of PCI Synthesis addresses trends, regulatory and supply chain hurdles, and quality concerns

  • Limiting APIs in Manufacturing Effluent

    Limiting APIs in Manufacturing Effluent

    Joan Tell, Robert Drinane, Bruce Naumann, Jessica Vestel, and Gregory Gagliano, Merck & Co., Inc.||June 2, 2016
    An approach for setting limits on pharmaceuticals discharged in manufacturing effluent

  • Biopharma CMO Market Trends

    Biopharma CMO Market Trends

    Tim Wright, Editor||June 2, 2016
    Continued strong growth in biopharma industry is being driven by biosimilars

  • Continuous Pharmaceutical Processes and Their Demands

    Continuous Pharmaceutical Processes and Their Demands

    Girish Malhotra, EPCOT International||April 5, 2016
    A look at the unique characteristics of continuous processes in pharmaceutical manufacturing.